HiJAKing Immunotherapy-Resistant Melanoma for a Cure

Immune checkpoint blockers (ICBs) have brought great promise to patients with advanced melanoma, a tumor type that was claimed largely incurable not long ago. However, therapeutic resistance to ICBs has limited their utility in the clinic. Here, we provide a commentary on recent research endeavors c...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Lewis Zhichang, Shen, Hongxing, Ojo, Oluwagbemiga A, Bonner, James A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020808/
https://www.ncbi.nlm.nih.gov/pubmed/36640142
http://dx.doi.org/10.1093/oncolo/oyac270
_version_ 1784908348366258176
author Shi, Lewis Zhichang
Shen, Hongxing
Ojo, Oluwagbemiga A
Bonner, James A
author_facet Shi, Lewis Zhichang
Shen, Hongxing
Ojo, Oluwagbemiga A
Bonner, James A
author_sort Shi, Lewis Zhichang
collection PubMed
description Immune checkpoint blockers (ICBs) have brought great promise to patients with advanced melanoma, a tumor type that was claimed largely incurable not long ago. However, therapeutic resistance to ICBs has limited their utility in the clinic. Here, we provide a commentary on recent research endeavors concerning ICB resistance in melanoma patients.
format Online
Article
Text
id pubmed-10020808
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-100208082023-03-18 HiJAKing Immunotherapy-Resistant Melanoma for a Cure Shi, Lewis Zhichang Shen, Hongxing Ojo, Oluwagbemiga A Bonner, James A Oncologist Commentaries Immune checkpoint blockers (ICBs) have brought great promise to patients with advanced melanoma, a tumor type that was claimed largely incurable not long ago. However, therapeutic resistance to ICBs has limited their utility in the clinic. Here, we provide a commentary on recent research endeavors concerning ICB resistance in melanoma patients. Oxford University Press 2023-01-14 /pmc/articles/PMC10020808/ /pubmed/36640142 http://dx.doi.org/10.1093/oncolo/oyac270 Text en © The Author(s) 2023. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentaries
Shi, Lewis Zhichang
Shen, Hongxing
Ojo, Oluwagbemiga A
Bonner, James A
HiJAKing Immunotherapy-Resistant Melanoma for a Cure
title HiJAKing Immunotherapy-Resistant Melanoma for a Cure
title_full HiJAKing Immunotherapy-Resistant Melanoma for a Cure
title_fullStr HiJAKing Immunotherapy-Resistant Melanoma for a Cure
title_full_unstemmed HiJAKing Immunotherapy-Resistant Melanoma for a Cure
title_short HiJAKing Immunotherapy-Resistant Melanoma for a Cure
title_sort hijaking immunotherapy-resistant melanoma for a cure
topic Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020808/
https://www.ncbi.nlm.nih.gov/pubmed/36640142
http://dx.doi.org/10.1093/oncolo/oyac270
work_keys_str_mv AT shilewiszhichang hijakingimmunotherapyresistantmelanomaforacure
AT shenhongxing hijakingimmunotherapyresistantmelanomaforacure
AT ojooluwagbemigaa hijakingimmunotherapyresistantmelanomaforacure
AT bonnerjamesa hijakingimmunotherapyresistantmelanomaforacure

Ejemplares similares